Schmidt Bettina, Anastasiadis Aristotelis G, Seifert Hans-Helge, Franke Knut H, Oya Mototsugu, Ackermann Rolf
Department of Urology, Heinrich-Heine Universität, Düsseldorf, Germany.
Anticancer Res. 2003 Sep-Oct;23(5A):3991-9.
The purpose of this study was to establish a quantitative standardized RT-PCR for the detection of Prostate Specific Membrane Antigen (PSMA)-expressing circulating cells and to evaluate clinical relevance in patients undergoing radical retropubic prostatectomy (RRP) for clinically localized prostate cancer (PCa).
An external standard molecule (PSMA MIMIC) was constructed for standardization of PSMA RT-PCR reactions. It has the same sequence as endogenous PSMA, except for a central 85 bp deletion, allowing the amplification of both targets simultaneously with nearly the same amplification characteristics as in a nested PCR. PSMA RT-PCR was performed from peripheral blood samples of 73 patients with clinically localized PCa, 4 with metastatic PCa, 27 with benign prostatic hyperplasia (BPH) and 27 controls. Pre, intra- and postoperative blood samples were tested for circulating PSMA expressing cells in 54 out of 73 patients with clinically localized PCa. We also tested intraoperative blood samples of 19 BPH patients treated by transurethral or open surgery.
Endogenous PSMA signals from PCa patients varied between 850 and 9900 transcript molecules, corresponding to 2-20 PSMA-expressing cells/ml blood. Standardized RT-PCR using the PSMA MIMIC molecule revealed a significant decrease of "false-positives" in cancer-free controls (p = 0.004). Controls could clearly be distinguished from prostate cancer patients based on PSMA PCR positivity (p = 0.003). Thirty-two % of patients with localized prostate cancer, 11% of BPH patients and 7% of healthy controls were positive in standardized assays compared to 48%, 30% and 27% without PSMA MIMIC, respectively. Preoperatively, a correlation with tumor stage (p = 0.030), grade (p = 0.035) and Gleason Score (p = 0.03) could be demonstrated in clinically localized PCa patients. Dissemination of prostate cells during surgery occurred in 32% of the RRPs and 21% of BPH patients. Positive PCR signals from intraoperative blood samples correlated with positive lymph node status (p = 0.007) and tumor grade (p = 0.005). Postoperative positive results correlated with grade (p = 0.012) and Gleason Score (p = 0.035).
Counseling the patient with clinically localized prostate cancer can be challenging. Surgery may be, in retrospect, inappropriate in a number of patients due to preoperative understaging. This newly constructed external standard allows quantitative detection of circulating prostate cells, and therefore may open new perspectives for PSMA RT-PCR techniques as diagnostic assays and tools for post-therapeutic follow-up.
本研究的目的是建立一种定量标准化逆转录聚合酶链反应(RT-PCR),用于检测表达前列腺特异性膜抗原(PSMA)的循环细胞,并评估其在接受根治性耻骨后前列腺切除术(RRP)治疗临床局限性前列腺癌(PCa)患者中的临床相关性。
构建一种外部标准分子(PSMA模拟物)用于PSMA RT-PCR反应的标准化。它与内源性PSMA具有相同的序列,但中间有一个85bp的缺失,使得两个靶标能够同时扩增,其扩增特性与巢式PCR几乎相同。对73例临床局限性PCa患者、4例转移性PCa患者、27例良性前列腺增生(BPH)患者和27例对照者的外周血样本进行PSMA RT-PCR检测。在73例临床局限性PCa患者中的54例患者中,检测了术前、术中和术后血样中表达循环PSMA的细胞。我们还检测了19例经尿道或开放手术治疗的BPH患者的术中血样。
PCa患者的内源性PSMA信号在850至9900个转录分子之间变化,相当于每毫升血液中有2 - 20个表达PSMA的细胞。使用PSMA模拟物分子进行标准化RT-PCR显示,无癌对照中的“假阳性”显著减少(p = 0.004)。根据PSMA PCR阳性情况,可将对照与前列腺癌患者明显区分开来(p = 0.003)。在标准化检测中,32%的局限性前列腺癌患者、11%的BPH患者和7%的健康对照呈阳性,而在未使用PSMA模拟物时,这一比例分别为48%、30%和27%。术前,在临床局限性PCa患者中可证明与肿瘤分期(p = 0.030)、分级(p = 0.035)和Gleason评分(p = 0.03)存在相关性。手术过程中前列腺细胞的播散在32%的RRP患者和21%的BPH患者中发生。术中血样的阳性PCR信号与阳性淋巴结状态(p = 0.007)和肿瘤分级(p = 0.005)相关。术后阳性结果与分级(p = 0.012)和Gleason评分(p = 0.035)相关。
为临床局限性前列腺癌患者提供咨询可能具有挑战性。回顾来看,由于术前分期不足,一些患者的手术可能并不合适。这种新构建的外部标准允许定量检测循环前列腺细胞,因此可能为PSMA RT-PCR技术作为诊断检测方法和治疗后随访工具开辟新的前景。